Translation: Original published in Finnish on 05/15/2026 at 07:30 am EEST

The consolidation of the digital pathology market finally took a step forward last week. Swiss company Roche announced the acquisition of US-based PathAI for a maximum of 1.05 BUSD  (750 MUSD in cash, plus up to 300 MUSD in milestone payments). The deal continues a series of strategic moves seen in the industry over the past 12–18 months. In our view, Aiforia's strong position in AI-powered pathology image analysis brings the stock potential as an acquisition target. On the other hand, there are still significant uncertainties regarding the speed of market development and thus the sector's revenue growth prospects.

Roche–PathAI transaction: The latest news in industry consolidation

Roche has been investing in digital pathology for quite some time. The company aims to build a comprehensive workflow that covers slide staining (where Roche is already strong through its Ventana business), imaging (scanners), and image management and analysis (AI). PathAI fits directly into the last category. Roche and PathAI have been partners since 2021, and their collaboration was expanded in 2024 specifically to develop AI-powered CDx  (Companion Diagnostics) algorithms. There is no reliable information available regarding the valuation of the PathAI transaction, as PathAI's figures are not public due to it being a private company. 

Several acquisitions have taken place in 2025–26

In addition to the Roche–PathAI deal, other arrangements have also been made in the industry:

• Tempus AI acquired Paige in 2025: Combining Paige's image analysis with Tempus' broader genomics and AI platform.
• AstraZeneca acquired Modella AI in early 2026: the developer of AI foundation models merged with AstraZeneca's in-house drug development and CDx expertise.
• Evident (Olympus' microscopy spin-off) acquired Pramana in 2025: Praman's autonomous slide scanners were combined with Evident's microscopy and optics expertise.
• Leica Biosystems made a strategic investment in Indica Labs in 2025: Integrating AI expertise into the overall workflow, as in the PathAI deal.

Aiforia is also a potential acquisition target due to its strong position

We consider Aiforia a potential acquisition target, as described in our extensive report. We believe the company's position is strong, based on its broad (and growing) offering of regulatory-approved AI models, customer wins, and increasing partnerships. 

Our stance on Aiforia's strong position is also supported by a recent independent study in Virchows Archiv in March 2026 (Winter et al.). The authors started with 367 identified digital pathology companies. After multi-stage filtering, 14 AI platforms remained that meet the requirements for CE-IVD certification, full-scale case management, and integrated or integratable AI features in the European market. Based on the study, Aiforia has one of the broadest portfolios of CE-IVDR certified proprietary algorithms in the comparison table. Only six of the platforms offer their own algorithms – the rest rely entirely on third-party modules. For example, compared to PathAI and Indica Labs mentioned above, Aiforia offers significantly more CE-IVDR models. Aiforia also appears to fit perfectly with the criteria that researchers recommend considering when choosing a digital pathology solution.